Table 2.
Proportion of patients with reduction in tumor size >0%, >10% and >30%, for patients with vs without selected resistance/sensitivity biomarkers
| Drug | Tumor type | Biomarker |
% Biomarker-positive patients with tumor shrinkagea |
% Biomarker-negative patients with tumor shrinkagea |
||||
|---|---|---|---|---|---|---|---|---|
| Tumor shrank > 0% | Tumor shrank > 10% | Tumor shrank > 30% | Tumor shrank > 0% | Tumor shrank > 10% | Tumor shrank > 30% | |||
| Panitumumab [52] |
Colorectal |
KRAS wild type |
57% |
50% |
25% |
4% |
1% |
0% |
| Erlotinib [84] |
NSCLC |
EGFR mutant |
100% |
83% |
72% |
28% |
12% |
8% |
| Erlotinib [85] |
NSCLC |
EGFR mutant |
100% |
83% |
50% |
31% |
17% |
3% |
| Erlotinib [86] |
NSCLC |
EGFR mutant |
90% |
88% |
76% |
|
|
|
| Erlotinib [87] |
NSCLC |
EGFR mutant |
100% |
80% |
70% |
|
|
|
| Gefitinib [88] |
NSCLC |
EGFR mutant |
95% |
95% |
63% |
72% |
38% |
10% |
| Gefitinib [89] |
NSCLC |
EGFR mutant |
91% |
82% |
55% |
67% |
33% |
0% |
| Erlotinib or gefitinib [63] |
NSCLC |
EGFR mutant |
97% |
91% |
84% |
45% |
22% |
9% |
| Crizotinib [90] |
NSCLC |
EML4/ALK fusion |
94% |
88% |
69% |
|
|
|
| Vemurafenib [8] | Melanoma | BRAF V600E | 96% | 93% | 76% | |||
a. Calculated from manual measurement of available waterfall plots.